Bristol renews Ixsys collaboration with up to $40 mil. for research in solid tumor antigen drug targets.
Executive Summary
BRISTOL-MYERS SQUIBB RENEWS IXSYS AGREEMENT WITH $40 MIL. INVESTMENT over three years for research to identify solid tumor-related antigens for therapeutic targets, the companies announced Oct. 16. Under the new agreement, BMS will provide $18 mil. up front in equity and research funding. Future milestone payments could bring the total to $40 mil.